Scynexis (SCYX) Total Non-Current Liabilities (2013 - 2026)

Scynexis (SCYX) posted Total Non-Current Liabilities of $17.4 million for Q1 2026, up 133.78% on a QoQ basis from $7.5 million in Q4 2025, and up 41.81% year-over-year from $12.3 million in Q1 2025.

Scynexis (SCYX) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends

Scynexis' Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $17.4 million for Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 41.81% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.4 million (up 41.81% YoY) and the FY2025 annual result came in at $7.5 million, down 72.97% from the prior year.
  • Total Non-Current Liabilities was $17.4 million for Q1 2026 at Scynexis, up from $7.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $85.1 million in Q2 2022 and bottomed at $7.5 million in Q4 2025.
  • A 5-year average of $36.5 million and a median of $31.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2025 — Total Non-Current Liabilities tumbled 72.97% — and 2026, when it jumped 41.81%.
  • Scynexis' Total Non-Current Liabilities stood at $66.0 million in 2022, then tumbled by 48.82% to $33.8 million in 2023, then fell by 18.37% to $27.6 million in 2024, then tumbled by 72.97% to $7.5 million in 2025, then surged by 133.78% to $17.4 million in 2026.
  • Business Quant data shows SCYX's Total Non-Current Liabilities at $17.4 million in Q1 2026, $7.5 million in Q4 2025, and $11.1 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 599.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 6.26 Bn
10 Scynexis 21.55 Mn -15.20 Mn - 17.42 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 17.42 Mn
Dec 31, 2025 7.45 Mn
Sep 30, 2025 11.10 Mn
Jun 30, 2025 13.33 Mn
Mar 31, 2025 12.28 Mn
Dec 31, 2024 27.57 Mn
Sep 30, 2024 29.30 Mn
Jun 30, 2024 29.40 Mn
Mar 31, 2024 31.95 Mn
Dec 31, 2023 33.77 Mn
Sep 30, 2023 31.96 Mn
Jun 30, 2023 31.69 Mn
Mar 31, 2023 59.89 Mn
Dec 31, 2022 65.98 Mn
Sep 30, 2022 67.35 Mn
Jun 30, 2022 85.07 Mn
Mar 31, 2022 64.71 Mn
Dec 31, 2021 75.23 Mn
Sep 30, 2021 70.17 Mn
Jun 30, 2021 64.36 Mn